Clinical Trial Update: Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CD19-targeted CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19-targeted CAR-T cell therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Status: NOT_YET_RECRUITING